Eupraxia Pharmaceuticals Inc (EPRX) FinancialsEPRXEupraxia Pharmaceuticals Inc

Evaluating the bottom line, Eupraxia Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -108.45%, provide a clear picture of how effectively EPRX converts its operational activities into shareholder value.

In the context of the broader market, EPRX competes directly with industry leaders such as ALT and ARVN. With a market capitalization of $441.04M, it holds a significant position in the sector. When comparing efficiency, EPRX's gross margin of N/A stands against ALT's N/A and ARVN's 96.40%. Such benchmarking helps identify whether Eupraxia Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eupraxia's financial performance indicates ongoing investment in R&D, with a current ratio of 16.00 showing strong liquidity despite net losses. The company has cash and equivalents of $58.5 million, which is sufficient to fund operations into the second half of 2028.